Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Growth in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 114,800 shares, a growth of 326.8% from the December 31st total of 26,900 shares. Based on an average daily trading volume, of 129,900 shares, the short-interest ratio is currently 0.9 days. Currently, 0.2% of the shares of the company are sold short.

Xtant Medical Stock Up 14.6 %

Shares of NYSEAMERICAN XTNT traded up $0.08 during trading on Friday, hitting $0.61. 95,921 shares of the company were exchanged, compared to its average volume of 59,827. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. Xtant Medical has a 12-month low of $0.33 and a 12-month high of $1.30. The firm has a market cap of $84.80 million, a PE ratio of -4.69 and a beta of 0.33.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $27.94 million for the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%.

Hedge Funds Weigh In On Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC grew its holdings in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 70.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 515,006 shares of the medical device company's stock after purchasing an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 target price on shares of Xtant Medical and gave the stock a "buy" rating in a research note on Friday, October 18th.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.